Skin cancer detection support in primary care settings.
FDA cleared via Breakthrough Device pathway — first device of its kind authorized for primary-care use.
Vendor materials describe the Breakthrough Device history.
Peer-reviewed real-world deployment article in npj Digital Medicine (Nature portfolio) — one of the only entries in this scan backed by a genuinely independent publication documenting actual deployment rather than just regulatory clearance.
Real-world primary-care deployment documented in the peer-reviewed literature, not just claimed by the vendor.
Read the full npj Digital Medicine paper before publishing, to extract precise sensitivity/specificity and sample-size figures rather than citing the existence of the study alone.
This profile is not medical advice or an endorsement. Hospitals should perform their own due diligence (regulatory compliance, GDPR, cybersecurity, integration, local clinical validation). How we evaluate
Every profile documents the precise indication, regulatory status, vendor-supported and independent evidence, real-world deployment, limits and dated sources.
A independent systematic review or prospective multicentre study · B at least one independent peer-reviewed study · C peer-reviewed, vendor-supported · D vendor claims only.
Vendors, authors and clinicians can request a correction. Corrections are dated on the profile.